FDA-approved virus engineered to specifically kill cancer cells
BioVex has raised €76M across 3 funding rounds from 13 investors, most recently a Series D+ round in Nov 2009. Based in Oxton, UK; founded 1999; active in Healthtech. Acquired by Amgen in 2010. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2009-11-01 | Series D+ | €20M | Morningside Group,Sectoral Asset Management,Ventech,Ysios Capital | View deal → |
| 2009-03-01 | Series D+ |
| €32M |
| Innoven Partners,New Science Ventures,Omnes Venture Capital,Scottish Equity Partners |
| View deal → |
| 2003-10-01 | Series C | €24M | ABN AMRO,Avalon Ventures,CLSA,LDC,Temasek | View deal → |
